Search results for "isoxazole"

showing 10 items of 100 documents

Synthesis and herbicidal activity of isoxazole-substituted 1-aminoethylphosphonates and 1-hydroxyethylphosphonates

1994

Isoxazole‐substituted 1‐aminoethyl‐ and 1‐hydroxyethyiphosphonates were synthesized by a multi‐step procedure and were screened for herbicidal activity against Lepidium sativum L. and Cucumis sativus L. All the synthesized compounds exhibited notable herbicidal activity.

Lepidium sativumchemistry.chemical_compoundbiologyChemistryStereochemistryBiological activityIsoxazolebiology.organism_classificationApplied Microbiology and BiotechnologyChemical synthesisCucurbitaceaeCucumisPesticide Science
researchProduct

Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition …

2007

The molecular mechanisms behind the anti-neoplastic effects of non-steroidal anti-inflammatory drugs (NSAIDs) are not completely understood and cannot be explained by the inhibition of the cyclooxygenase (COX) enzymes COX-1 and COX-2 alone. We previously reported that both the selective COX-1 inhibitor SC-560 and the selective COX-2 inhibitor CAY10404 exhibit anti-tumor effects in human hepatoma cells. NSAID inhibitors have many COX-independent actions and, among others, the mitogen-activated protein kinase (MAPK) pathways are targets for NSAIDs. Here, we examined the role of MEK/ERK1/2 signaling in the anti-neoplastic effects of both selective COX-1 and COX-2 inhibitors in two human hepato…

MAPK/ERK pathwayCancer ResearchCarcinoma HepatocellularTime FactorsBlotting WesternApoptosisPharmacologyCOX-1 COX-2 NSAIDs MEK1/2 ERK1/2NitrilesButadienesTumor Cells CulturedHumansCyclooxygenase InhibitorsSulfonesEnzyme InhibitorsPhosphorylationProtein kinase ACell ProliferationPharmacologychemistry.chemical_classificationMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase KinasesMitogen-Activated Protein Kinase 3biologyDose-Response Relationship DrugLiver NeoplasmsCytochromes cLong-term potentiationDrug SynergismIsoxazolesFlow CytometryEnzymeOncologychemistryCyclooxygenase 2CaspasesCancer cellbiology.proteinCyclooxygenase 1Molecular MedicineMEK-ERK PathwayPyrazolesDrug Therapy CombinationCyclooxygenaseHepatoma cellCancer biologytherapy
researchProduct

Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' fi…

2006

International audience; BACKGROUND: The objective was to develop a clinical practice format for choosing a second-line disease-modifying anti-rheumatic drug (DMARD) after a 6-month course of a first-line DMARD in patients with early RA. METHODS: A panel of 34 experts selected treatment option from various scenarios using the Thurstone pairwise method. The experts had to choose between two proposed DMARDs without proposing other options. The scenarios were obtained using the three items: DAS28, rheumatoid factor status and radiographic structural damage. A sample of 240 among 480 scenarios for each expert was taken at random. Responses given by at least 20% of the experts were considered per…

MESH: Antirheumatic AgentsMESH: Treatment FailureDiseaseReceptors Tumor Necrosis FactorEtanerceptArthritis Rheumatoid0302 clinical medicineMESH: Practice Guidelines as Topic030212 general & internal medicineTreatment Failureskin and connective tissue diseasesMESH: Immunoglobulin GMESH: Arthritis RheumatoidAnti rheumatic drugs3. Good healthClinical PracticeMESH: Methotrexate[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemRheumatoid arthritisAntirheumatic AgentsPractice Guidelines as TopicDrug Therapy CombinationLeflunomidemusculoskeletal diseasesmedicine.medical_specialtyMESH: Rheumatoid FactorFirst lineMESH: Drug Administration ScheduleDrug Administration ScheduleDecision Support Techniques03 medical and health sciencesRheumatologyRheumatoid FactorDmard therapymedicineRheumatoid factorHumansIntensive care medicine030203 arthritis & rheumatologyMESH: HumansMESH: Sulfasalazinebusiness.industryMESH: Biological MarkersMESH: Decision Support TechniquesEarly rheumatoid arthritisIsoxazolesmedicine.diseaseMESH: Receptors Tumor Necrosis FactorRadiographySulfasalazineMESH: Drug Therapy CombinationMethotrexateMESH: IsoxazolesImmunoglobulin GPhysical therapybusinessBiomarkersJoint bone spine
researchProduct

Synthesis and Muscarinic Activity of Isoxazole-substituted 1,2,5,6-Tetrahydropyridines

1994

MalePyridinesGuinea PigsCholinergic AgentsPharmaceutical ScienceMuscarinic acetylcholine receptor M3Muscle SmoothMuscarinic acetylcholine receptor M2Biological activityIsoxazolesMuscarinic acetylcholine receptor M1In Vitro Techniqueschemistry.chemical_compoundchemistryBiochemistryDrug DiscoveryMuscarinic acetylcholine receptorMuscarinic acetylcholine receptor M5Muscarinic acetylcholine receptor M4AnimalsRabbitsIsoxazoleMuscle ContractionArchiv der Pharmazie
researchProduct

Brain-Derived Neurotrophic Factor But Not Forced Arm Use Improves Long-Term Outcome After Photothrombotic Stroke and Transiently Upregulates Binding …

2008

Background and Purpose— Both application of neurotrophic factors like brain-derived neurotrophic factor (BDNF) and constraint-induced movement therapy like forced arm use have been shown to potentially improve outcome after stroke. The aim of the present study was to check whether postischemic long-term outcome correlates to specific modifications in the abundance of various neurotransmitter receptors. Methods— Adult male Wistar rats were subjected to photothrombotic ischemia and assigned to various treatment groups (n=5 each) with end points at 3 and 6 weeks: (1) ischemic control (saline); (2) BDNF (ischemia, 20 μg BDNF); (3) forced arm use (ischemia, saline, and ipsilateral plaster cast …

MaleRestraint PhysicalMotor ActivityLigandsDownregulation and upregulationNeurotrophic factorsForelimbmedicineAnimalsRats WistarReceptorGABA Agonistsalpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic AcidStrokePhysical Therapy ModalitiesAdvanced and Specialized NursingBrain-derived neurotrophic factorMuscimolbusiness.industryBrain-Derived Neurotrophic FactorGlutamate receptorBrainCerebral Infarctionmedicine.diseaseRatsUp-RegulationStrokemedicine.anatomical_structureReceptors Glutamatenervous systemAnesthesiaExcitatory postsynaptic potentialAutoradiographyNeurology (clinical)Dizocilpine MaleateIntracranial ThrombosisForelimbCardiology and Cardiovascular MedicinebusinessExcitatory Amino Acid AntagonistsNeuroscienceStroke
researchProduct

Differential effect of beta-N-oxalylamino-L-alanine, the Lathyrus sativus neurotoxin, and (+/-)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate …

2000

We studied the effect of beta-oxalylamino-L-alanine, a glutamate analog present in Lathyrus sativus seeds and implicated in the etiopathogenesis of neurolathyrism, and (+/-)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate on the extracellular levels of aspartate, glutamate and taurine in the primary motor cortex of freely moving rats. We found that while both neurotoxins increase the level of aspartate and glutamate, only (+/-)-alpha(-amino-3-hydroxy-5-methylisoxazole-4-propionate is able to modulate the level of taurine. GYKI-52466, a non-competitive non-NMDA antagonist, inhibited beta-oxalylamino-L-alanine-induced increase of aspartate, but not that of glutamate. Conversely, this ant…

MaleTaurineTaurineMicrodialysisGlutamic AcidTetrodotoxinReceptors N-Methyl-D-AspartateRats Sprague-DawleyCellular and Molecular Neurosciencechemistry.chemical_compoundGlutamate aspartate transporterNeurotoxinAnimalsNeurotransmitteralpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic AcidAlaninechemistry.chemical_classificationAspartic AcidbiologyGlutamate receptorMotor CortexAmino Acids DiaminoBrainCell BiologyCorpus StriatumAmino acidRatschemistryBiochemistrybiology.proteinPotassiumbeta-AlanineNMDA receptorExtracellular SpaceExcitatory Amino Acid AntagonistsNeurochemistry international
researchProduct

Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.

1993

AbstractThe active metabolite of leflunomide, A77 1726 inhibits the proliferation of a variety of mammalian cell lines in culture. Epidermal growth factor (EGF)-dependent proliferation is inhibited by A77 1726 at an effective dose of 30–40 μM. A77 1726 appears to directly inhibit the EGF receptor tyrosine-specific kinase activity both in intact cells and purified EGF receptors at the same effective dose. These data suggest that leflunomide inhibits cellular proliferation by the inhibition of tyrosine-specific kinase activities.

MaleToluidinesmedicine.medical_treatmentBiophysicsHydroxybutyratesBiochemistryKB CellsCell LineHuman foreskin fibroblast cellStructural BiologyEpidermal growth factorNitrilesGeneticsmedicineTumor Cells CulturedAnimalsHumansEpidermal growth factor receptorKinase activityPhosphorylationReceptorMolecular BiologyCells CulturedSkinAniline CompoundsbiologyCell growthKinaseEpidermal growth factor receptorGrowth factorAnti-Inflammatory Agents Non-SteroidalCell BiologyIsoxazolesFibroblastsTyrosine-specific kinaseCell biologyErbB ReceptorsBiochemistryCrotonatesbiology.proteinCarcinoma Squamous CellPlatelet-derived growth factor receptorLeflunomideFEBS letters
researchProduct

Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice

2008

Efflux transporters, like P-glycoprotein (P-gp), may limit the access of drugs to the brain via the blood-brain barrier. The antipsychotic drug risperidone and its active metabolite 9-hydroxyrisperidone (paliperidone) are substrates of P-gp. Motor behavior of P-gp deficient mice (mdr1a/1b (-/-, -/-)) and wild type animals on a rotarod after acute doses of risperidone or haloperidol, a nonsubstrate of P-gp, were analysed aiming to show that P-gp substrate properties of an antipsychotic drug have functional consequences. Behavioral tests revealed dose-dependent effects of 0.3-3 mg/kg risperidone in wild type animals 0.5-12 h after i.p. injection of the drug. In knockout mice the 0.3 mg/kg dos…

Malemedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BTime Factorsmedicine.drug_classAtypical antipsychoticMotor ActivityPharmacologyMiceBehavioral NeurosciencePharmacokineticsInternal medicinePaliperidone PalmitatemedicineHaloperidolAnimalsPaliperidoneATP Binding Cassette Transporter Subfamily B Member 1Chromatography High Pressure LiquidMice KnockoutPaliperidone PalmitateRisperidoneBehavior AnimalDose-Response Relationship DrugChemistryDopamine antagonistBrainIsoxazolesRisperidonePyrimidinesEndocrinologyPsychotropic drugArea Under CurveHaloperidolATP-Binding Cassette TransportersAntipsychotic Agentsmedicine.drugBehavioural Brain Research
researchProduct

Significance of gamma-glutamyltranspeptidase in exocrine pancreatic amino acid transport.

1991

The exocrine pancreas is rich in gamma-glutamyltranspeptidase (GGT, EC 2.3.2.2) and exhibits high rates of amino acid transport and protein synthesis. The role of the gamma-glutamyl cycle in mediating neutral amino acid transport in the isolated perfused rat pancreas was investigated using acivicin, an inhibitor of GGT, and a rapid dual isotope dilution technique. When treatment in vivo with acivicin (50 mg/kg) was followed 1 h later by continuous perfusion of the isolated pancreas with 10 microM acivicin, GGT levels decreased from 53 +/- 3 IU/g to 4.9 +/- 1.5 IU/g. This marked inhibition of GGT activity was not associated with decreased uptake for either L-alanine or L-glutamine, suggestin…

Malemedicine.medical_specialtyGlutamineBiophysicsIndicator Dilution TechniquesBiologydigestive systemBiochemistryEpitheliumchemistry.chemical_compoundIn vivoInternal medicineNeutral amino acid transportmedicineAnimalsAmino AcidsAcivicinPancreasEpithelial polaritychemistry.chemical_classificationAlanineBiological TransportRats Inbred StrainsCell BiologyIsoxazolesgamma-Glutamyltransferasedigestive system diseasesEpitheliumAmino acidRatsEnzymemedicine.anatomical_structureEndocrinologychemistryPancreasBiochimica et biophysica acta
researchProduct

Glucocorticoids as modulators of expression and activity of Antithrombin (At): potential clinical relevance.

2014

Abstract Introduction An inverse relationship has been reported between decreased postoperative Antithrombin (AT) plasmatic levels and the incidence of complications. We hypothesized that Nuclear Hormone Receptors could modulate the expression of SERPINC1 , encoding AT, through a Hormone Regulatory Element present in its promoter, and thus hormone analogs could be a pharmacological complement in surgical procedures to activate endogenous AT synthesis. Materials and Methods The expression of SERPINC1 was analyzed in HepG2 cells by quantitative RT-PCR and Western Blot. Two studies were conducted with (a) patients submitted to cardiac surgery with cardiopulmonary bypass receiving (n =17) or no…

Malemedicine.medical_specialtyMolecular Sequence DataReceptors Cytoplasmic and NuclearRetinoid X receptorLigandsAntithrombinsCohort StudiesRetinoidsInternal medicinemedicineHumansGlucocorticoidsDexamethasoneAgedCardiopulmonary BypassBase Sequencebusiness.industryAntithrombinRNA-Binding ProteinsHematologyHep G2 CellsIsoxazolesMiddle AgedEndocrinologyRetinoid X ReceptorsTreatment OutcomeMethylprednisoloneNuclear receptorHemostasisFemaleCortisonebusinessHormonemedicine.drugThrombosis research
researchProduct